ils-920

Small moleculeexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Feb 1, 2009 (NCT00827190)

Timeline

2000s

Jan 1, 2009
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Ischemic Stroke · Phase 1

Mechanism of action

FK506 binding protein 4INHIBITOR
FKBP4 inhibitor
- Peptidyl-prolyl cis-trans isomerase FKBP4 (FKBP4) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CO[C@@H]1C/C(C)=C\[C@H]2CC[C@@H]([C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]3CC[C@@H](O)[C@H](OC)C3)OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H](CC[C@H]3C)C1)N(c1ccccc1)O2

Mol. weight: 1037.34 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL508360 ↗

Also known as

ils-920
ils-920

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00827190	Phase 1	Feb 1, 2009	Pfizer, Wyeth

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Pfizer	For profit	1	1	1	2009
Wyeth	For profit	1	0	1	2009

2 organizations

Page 1 / 1